Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
Total Valuation
BioMarin Pharmaceutical has a market cap or net worth of $10.78B. The enterprise value is $19.53B.
Market Cap$10.78B
Enterprise Value$19.53B
Share Statistics
BioMarin Pharmaceutical has 191,775,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding191,775,670
Owned by Insiders0.54%
Owned by Institutions40.19%
Financial Efficiency
BioMarin Pharmaceutical’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 5.98%.
Return on Equity (ROE)0.08
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)5.98%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee938.79K
Profits Per Employee140.41K
Employee Count3,040
Asset Turnover0.41
Inventory Turnover0.47
Valuation Ratios
The current PE Ratio of BioMarin Pharmaceutical is 29.26. BioMarin Pharmaceutical’s PEG ratio is -0.43.
PE Ratio29.26
PS Ratio0.00
PB Ratio4.17
Price to Fair Value2.21
Price to FCF432.20
Price to Operating Cash Flow109.00
PEG Ratio-0.43
Income Statement
In the last 12 months, BioMarin Pharmaceutical had revenue of 2.85B and earned 426.86M in profits. Earnings per share was 2.13.
Revenue2.85B
Gross Profit2.27B
Operating Income484.21M
Pretax Income541.76M
Net Income426.86M
EBITDA650.86M
Earnings Per Share (EPS)2.13
Cash Flow
In the last 12 months, operating cash flow was 700.26M and capital expenditures -80.08M, giving a free cash flow of 620.18M billion.
Operating Cash Flow700.26M
Free Cash Flow620.18M
Free Cash Flow per Share3.23
Dividends & Yields
BioMarin Pharmaceutical pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.43
52-Week Price Change-33.85%
50-Day Moving Average59.32
200-Day Moving Average66.68
Relative Strength Index (RSI)39.22
Average Volume (3m)2.10M
Important Dates
BioMarin Pharmaceutical upcoming earnings date is Aug 5, 2025, TBA Not Confirmed.
Last Earnings DateMay 1, 2025
Next Earnings DateAug 5, 2025
Ex-Dividend Date―
Financial Position
BioMarin Pharmaceutical as a current ratio of 5.33, with Debt / Equity ratio of 23.53%
Current Ratio5.33
Quick Ratio3.29
Debt to Market Cap0.05
Net Debt to EBITDA-0.52
Interest Coverage Ratio38.23
Taxes
In the past 12 months, BioMarin Pharmaceutical has paid 114.90M in taxes.
Income Tax114.90M
Effective Tax Rate0.21
Enterprise Valuation
BioMarin Pharmaceutical EV to EBITDA ratio is 18.67, with an EV/FCF ratio of 25.56.
EV to Sales4.26
EV to EBITDA18.67
EV to Free Cash Flow25.56
EV to Operating Cash Flow21.21
Balance Sheet
BioMarin Pharmaceutical has $1.27B in cash and marketable securities with $595.65M in debt, giving a net cash position of -$676.68M billion.
Cash & Marketable Securities$1.27B
Total Debt$595.65M
Net Cash-$676.68M
Net Cash Per Share-$3.53
Tangible Book Value Per Share$27.40
Margins
Gross margin is 76.92%, with operating margin of 16.97%, and net profit margin of 14.96%.
Gross Margin76.92%
Operating Margin16.97%
Pretax Margin18.98%
Net Profit Margin14.96%
EBITDA Margin22.81%
EBIT Margin19.42%
Analyst Forecast
The average price target for BioMarin Pharmaceutical is $94.27, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$94.27
Price Target Upside67.62% Upside
Analyst ConsensusModerate Buy
Analyst Count18
Revenue Growth Forecast17.99%
EPS Growth Forecast152.10%